Accelerating mRNA Production:
Leveraging Synthetic DNA for Enhanced IVT Efficiency & Rapid Delivery
Wednesday, August 28, 2024
5:00 PM – 6:00 PM BST
In this webinar, leading experts from Syngoi, Quantoom, ReciBioPharm and Afrigen Biologics will discuss the pivotal role of synthetic DNA in optimizing mRNA production. The session will focus on recent advancements, showcasing how synthetic DNA is revolutionizing the In Vitro Transcription (IVT) process, yielding superior results and offering faster delivery times compared to traditional plasmid DNA methodologies.
Key Highlights:
- A comprehensive overview of synthetic DNA technology and its application in the production of mRNA
- Case studies and data demonstrating the efficiency and effectiveness of synthetic DNA in IVT, leading to improved yields and quality of mRNA
- Comparative metrics showcasing the superiority of synthetic DNA over plasmid DNA in terms of production speed, scalability, and consistency
- Discussions on how these advancements translate into faster delivery times and enhanced flexibility in mRNA therapeutics and vaccine development
- Q&A sessions where participants can interact with industry experts, gaining deeper insights into the practical applications and future potential of synthetic DNA in mRNA production
Why Attend?
- Gain a thorough understanding of the latest technological advancements in synthetic DNA
- Learn about the practical benefits and implementation strategies from industry leaders
Join us for an informative session that promises to broaden your knowledge and provide actionable insights into the future of mRNA production.
Syngoi Technologies is at the forefront of synthetic biology, specializing in the production of high-quality synthetic DNA. Syngoi’s synthetic DNA offers significant advantages over traditional plasmid DNA, including increased speed, precision, and scalability, making it ideal for applications in vaccine development and therapeutic manufacturing. By focusing on producing clean, linear DNA templates, Syngoi ensures higher yields and consistency in mRNA synthesis, enabling faster delivery times, and providing critical support for rapid response scenarios
Your Speakers:
Jose Vicente Pons
CEO
Julen Oyarzabal
CSO
Jose Castillo
CEO
Jing Zhu
Head of Process Development
Petro Terblanche
CEO
Dr Caryn Fenner
mRNA Hub Director
Rajen Naidoo
Commercial & Business Development
Brought to you by:
